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Gamma-Herpesvirus Latency Requires T Cell
Evasion during Episome Maintenance
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The gamma-herpesviruses persist as latent episomes in a dynamic lymphocyte pool. Their consequent need to express
a viral episome maintenance protein presents a potential immune target. The glycine–alanine repeat of the Epstein–
Barr virus episome maintenance protein, EBNA-1, limits EBNA-1 epitope presentation to CD8þ T lymphocytes (CTLs).
However, CTL recognition occurs in vitro, so the significance of such evasion for viral fitness is unclear. We used the
murine gamma-herpesvirus-68 (MHV-68) to define the in vivo contribution of cis-acting CTL evasion to host
colonisation. Although the ORF73 episome maintenance protein of MHV-68 lacks a glycine–alanine repeat, it was
equivalent to EBNA-1 in conferring limited presentation on linked epitopes. This was associated with reduced protein
synthesis and reduced protein degradation. We bypassed the cis-acting evasion of ORF73 by using an internal
ribosome entry site to express in trans-a CTL target from the same mRNA. This led to a severe, MHC class I–restricted
and CTL-dependent reduction in viral latency. Thus, despite MHV-68 encoding at least two trans-acting CTL evasion
proteins, cis-acting evasion during episome maintenance was essential for normal host colonisation.
Citation: Bennett NJ, May JS, Stevenson PG (2005) Gamma-herpesvirus latency requires T cell evasion during episome maintenance. PLoS Biol 3(4): e120.
Introduction
Latent herpesviruses can persist as episomes in quiescent
cells without viral protein expression. However, the gamma-
herpesviruses are characteristically latent in memory lym-
phocytes, which intermittently divide. Viral genomes must
therefore be replicated and segregated between daughter
cells in step with cellular mitosis. This requires a viral
episome maintenance protein, creating a potential target for
the immune recognition of latently infected cells. A glycine–
alanine repeat in the Epstein–Barr virus (EBV) episome
maintenance protein, EBNA-1 [1], inhibits its degradation [2]
and translation [3] such that EBNA-1 epitopes are poorly
presented to CD8þT lymphocytes (CTLs) [4,5,6]. However, the
in vivo effectiveness of the glycine–alanine repeat and its
quantitative contribution to host colonisation remain un-
known. In vitro studies have suggested that abortive EBNA-1
translation products still provide sufficient epitopes for
EBNA-1-specific CTLs to recognise latently infected B cells
[7,8,9].
In vivo immune function is difficult to analyse directly with
human viruses. However, the murid pathogen murine
gamma-herpesvirus-68 (MHV-68) affords an opportunity to
manipulate a gamma-herpesvirus in its natural host. MHV-68
is a gamma-2-herpesvirus [10], more closely related to the
Kaposi’s sarcoma–associated herpesvirus than to EBV [11],
but clear functional parallels exist between all three viruses.
Like EBV, MHV-68 causes an acute infectious mononucleosis-
like illness, associated with a massive expansion of latently
infected germinal centre B cells, and it persists in memory B
cells [12,13,14]. The episome maintenance protein of gamma-
2-herpesviruses is encoded by ORF73 [15]. Just as EBNA-1-
deficient EBV [16] and ORF73-deficient Kaposi’s sarcoma–
associated herpesvirus [17] fail to maintain latency in vitro,
ORF73-deficient MHV-68 has a profound latency deficit in
vivo [18,19].
At least twoMHV-68 gene products inhibit CTL recognition
of latently infected cells. The M3 chemokine-binding protein
[20,21] is abundantly secreted by lytic virus [22]. This co-exists
with latent virus in infected lymphoid tissue [14,23,24].
Bystander protection by M3 [25] probably explains why M3
disruption causes mainly a reduction in MHV-68 latency
amplification [26,27]. Protection by M3 may be quite context-
dependent [28] and probably functions best in acute infection,
before M3-specific immunity is established. A second MHV-68
CTL evasion protein, K3, degrades major histocompatibility
complex (MHC) class I heavy chains [29] and TAP (transporter
associated with antigen processing) [30]. K3 is transcribed in
latency as well as in the viral lytic cycle, and again protects
against CTLs during latency amplification [31]. However, K3 is
not expressed in all forms of latency: it is not detectable in the
MHV-68-infected S11 tumor line [32] or in persistently
infected, B cell–deficientmice [33]. Notably, ORF73 disruption
causes a much more profound latency deficit than does K3
disruption, implying that immune evasion by K3 is not
important in every cell expressing ORF73. These restrictions
on M3 and K3 function imply that further immune evasion
mechanisms contribute to MHV-68 latency.
Selective EBNA-1 expression occurs in normal EBV
persistence [34,35] and is characteristic of EBV-associated
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Burkitt’s lymphoma [36]. The gamma-2-herpesviruses pre-
sumably implement an equivalent program of selective
ORF73 expression. We have used MHV-68 to determine
the in vivo importance of avoiding epitope presentation
during episome maintenance. We first established that the
MHV-68 ORF73 is equivalent to EBNA-1 in reducing the
presentation of an MHC class I–restricted epitope linked to
it in cis. We then modified the ORF73 transcript to bypass
this evasion, and used the mutant virus to define the
consequences of epitope presentation for viral fitness. Our
analysis of MHV-68 implies that if MHC class I–restricted
viral epitope presentation occurs during gamma-herpesvirus
episome maintenance, even a relatively small CTL response
can very effectively clear latent infection.
Results
Limited Presentation of a CD8þ T Cell Epitope Linked in cis
to ORF73
As with EBNA-1, CTL epitopes in the MHV-68 ORF73 have
been hard to find, perhaps reflecting limited ORF73 entry
into the MHC class I antigen-processing pathway. To
determine whether ORF73 is similar to EBNA-1 in its
resistance to MHC class I–restricted antigen presentation,
we introduced the H2-Kb-restricted SIINFEKL epitope of
ovalbumin (OVA) near the ORF73 C-terminus (73-SC) or N-
terminus (73-SN). L929-Kb cells transfected with 73-SC or 73-
SN were poorly recognised by the SIINFEKL-specific hybrid-
oma, B3Z (Figure 1A), suggesting poor antigen processing.
There was no evidence for ORF73 inhibiting SIINFEKL
presentation from co-transfected OVA (Figure 1B). The
apparent immune evasion therefore acted in cis rather than
in trans, and it was not due to any ORF73 toxicity.
To identify possible contributions of the N-terminal and C-
terminal regions of ORF73 to its poor epitope presentation,
we made hybrids of OVA (amino acid residues 1–325) and 73-
SC using a shared PstI site (Figure 1C). N-terminal ORF73
(amino acid residues 1–150) diminished SIINFEKL presenta-
tion from OVA relatively little, suggesting that any inhibitory
segment was C-terminal of its PstI site (amino acid residues
151–314). With N-terminal OVA, SIINFEKL presentation
from 73-SC remained low.
A Key Region of ORF73 for cis-Acting Immune Evasion
We adopted two strategies to localise an inhibitory segment
C-terminal of the ORF73 PstI site. First, we fused the entire
ORF73 coding sequence to the C-terminus of OVA, thereby
inhibiting SIINFEKL presentation from OVA. C-terminal
truncation of the fusion protein (Figure 1D) up to the ORF73
HinDIII site (residue 278) then had little effect, but
truncation up the ORF73 KpnI site (residue 206) restored
SIINFEKL presentation somewhat. N-terminal truncation
(Figure 1E) to ORF73 residue 166 (OVA-73C) did not
compromise the inhibition, but further truncation to residue
186 (OVA-73B) and then residue 206 (OVA-73A) progres-
sively improved SIINFEKL presentation. These data were
consistent with the region of ORF73 encoding approximately
residues 170–220 (the shaded region in Figure 1D–1G)
reducing antigen presentation.
We also truncated 73-SN from its C-terminus and looked
for presentation of its N-terminal SIINFEKL epitope
(Figure 1F). With SIINFEKL in this context, the same C-
terminal truncations as in Figure 1D (amino acid residues 1–
204) gave no epitope presentation, presumably because
SIINFEKL was less efficiently processed from 73-SN than it
was from OVA. However, a further truncation up to the
ORF73 PstI site (residue 150) dramatically improved
SIINFEKL presentation. PCR-generated C-terminal trunca-
tions of 73-SN (Figure 1G) supported the idea of a region
just upstream of the ORF73 KpnI site (ORF73-SN-B)
limiting the presentation of SIINFEKL from 73-SN. These
results were therefore consistent with those shown in Figure
1D and 1E.
The Effects of ORF73 on the Turnover of Linked OVA
The inhibition of EBNA-1 epitope presentation by its
glycine–alanine repeat has been attributed principally to
reduced protein synthesis and secondarily to reduced protein
degradation [3]. We therefore analysed the effect of ORF73
on OVA turnover using constructs equivalent to those in
Figure 1E, except that we removed the signal sequence of
OVA to avoid any protein secretion (SOVA, Figure 2A). All
constructs were cloned into pcDNA3 and transfected into
293T cells. We observed a hierarchy of SOVA/ORF73 antigen
presentation (Figure 2B) similar to that seen with the OVA/
ORF73 hybrids: amino acids 206–314 of ORF73 (SOVA-73A)
reduced somewhat SIINFEKL presentation from SOVA;
amino acids 166–314 (SOVA-73C) reduced it further; includ-
ing an additional 40 amino acids of ORF73 (SOVA-73E) gave
no additional inhibition.
Steady-state protein levels, determined by immunoblotting
transfected cell lysates (Figure 2C), were greatest with SOVA,
followed by SOVA-73A, and least with SOVA-73D-E. Parallel
immunoblots for neomycin phosphotransferase II, expressed
from a different promoter of the same plasmid, showed no
significant variation in signal, arguing against an effect of
ORF73 on cell viability or transfection efficiency. Pulse-chase
metabolic labelling of transfected 293T cells and immuno-
precipitation with an OVA-specific antiserum (Figure 2D)
showed that all the ORF73/SOVA fusions were more stable
than SOVA alone, and that their labelling was reduced as
more ORF73 sequence was attached. The differences in
protein synthesis rate (Figure 2D) correlated with steady-state
protein levels (see Figure 1C). Using a variable labelling
window (Figure 2E), SOVA and SOVA-73A were detectable
after a 15-min pulse, whereas SOVA-73E was hard to discern
even after a 120-min pulse.
The apparent stability conferred by ORF73 on SOVA
(Figure 2D) was confirmed by further analysis of SOVA-73A,
the fusion protein that labelled most efficiently (Figure 2F).
After a 20-min pulse, most labelled SOVA was lost over the
next 2 h, whereas the labelled SOVA-73A was relatively well
maintained. Proteasome inhibition with lactacystin partially
stabilised SOVA, but it remained less stable than SOVA-73A.
Thus, the stability afforded by amino acids 206–314 of ORF73
appeared to extend beyond protection against proteasome-
mediated degradation. Overall, the cis-acting immune evasion
of ORF73 appeared functionally similar to that of EBNA-1, in
that reduced epitope presentation was associated with
reduced protein synthesis and reduced protein degradation.
In contrast to EBNA-1, these functions were mediated by
distinct regions of ORF73. The key region for inhibiting
epitope presentation (see Figure 1D–1G) corresponded to
that responsible for reducing protein synthesis.
PLoS Biology | www.plosbiology.org April 2005 | Volume 3 | Issue 4 | e1200639
Viral Immune Evasion in Latency
An MHV-68 Mutant That Lacks cis-Acting Immune Evasion
The region of ORF73 responsible for cis-acting immune
evasion—that encoding amino acids 170–220—shows consid-
erable amino acid homology to both EBNA-1 and the Kaposi’s
sarcoma–associated herpesvirus ORF73 [37]. Any mutagenesis
was therefore likely to compromise other ORF73 functions.
Also, altering this region would change the steady-state levels
of ORF73, with likely toxic effects in latently infected cells. In
order to keep ORF73 function intact, therefore, we bypassed
the cis-acting immune evasion not by mutating the ORF73
protein, but by modifying its mRNA. Thus, we inserted an
internal ribosome entry site (IRES) just downstream of the
Figure 1. Inhibition of MHC Class I–Restricted Epitope Presentation by Physical Linkage to ORF73
(A) The SIINFEKL epitope of OVA was introduced into ORF73 near either its N-terminus (ORF73-NC) or its C-terminus (ORF73-SC). Both
ORF73 derivatives were cloned into the pcDNA3 expression vector and compared with OVA in the same vector for their capacity to stimulate
the SIINFEKL-specific T cell hybridoma B3Z after transfection into L929-Kb cells. After 48 h, beta-galactosidase production was assayed by cell
lysis in the presence of chlorophenol-red-beta-D-galactoside and reading absorbance at 595 nm. nil, vector only.
(B) L929-Kb cells were co-transfected with OVA plus the plasmid indicated. C1–C4 are control plasmids, expressing MHV-68 ORFs 19, 30, 31, and
35, respectively. K3 degrades MHC class I heavy chains and m152 is a murine cytomegalovirus gene that retains MHC class I molecules in the
endoplasmic reticulum. Net absorbance = A595 with co-transfection  A595 with untransfected cells (,0.02).
(C) Hybrids of OVA and ORF73-SC were made to identify regions of ORF73 that inhibited SIINFEKL presentation. Responses are expressed as
100(A595 with plasmid  A595 with untransfected)/(A595 with OVA transfection  A595 with untransfected). nil, vector only. Mean 6 standard
deviation (SD) values of triplicate cultures are shown. Each graph is representative of at least three separate experiments. In at least one
experiment, equal transfection efficiency was confirmed by co-transfecting a GFP expression plasmid and checking fluorescence under
ultraviolet illumination.
(D) ORF73 was fused to the C-terminus of the OVA coding sequence in pcDNA3. C-terminal deletions were then made as shown. Each construct
was transfected into L929-H2-Kb cells. The shaded area in (D–G) highlights a region of ORF73 that appeared to be important for inhibiting
epitope presentation.
(E) N-terminal ORF73 truncations were generated by PCR and fused in frame to amino acid 325 of OVA. Each construct was transfected into
L929-H2-Kb cells and assayed for SIINFEKL presentation as in (D).
(F) Progressive truncations of ORF73-SNwere assayed for their capacity to present the SIINFEKL epitope to B3Z cells after transfection into L929-
Kb cells. Selective presentation from the ORF73-SN-PstI construct was confirmed in multiple experiments, including independent plasmid
preparations.
(G) PCR-generated C-terminal truncations of ORF73-SN were assayed for SIINFEKL presentation after transfection of L929-H2-Kb cells.
Deletions across the area identified as important for inhibiting epitope presentation in (D–E) again improved epitope presentation.
DOI: 10.1371/journal.pbio.0030120.g001
Figure 2. Inhibition of Epitope Presentation by ORF73 Fusion to OVA Correlates with Reduced Translation of the Fusion Protein
(A) N-terminal ORF73 truncations equivalent to those in Figure 1E were fused in frame to the C-terminus of OVA amino acids 41–325, thereby
removing both the OVA signal sequence and the ORF73 nuclear localisation signal.
(B) Serial dilutions of an expression plasmid containing each fusion gene were transfected into L929-H2-Kb cells as in Figure 1. SIINFEKL
presentation was assayed using beta-galactosidase production from the B3Z hybridoma.
(C) Equivalent transfected cells were immunoblotted with an anti-OVA rabbit serum (OVA). Fusion products are indicated by arrowheads where
visible. Parallel immunoblots for neomycin phosphotransferase II (NPT), which is expressed from a different promoter of the same plasmid
(pcDNA3), were used to control for transfection efficiency. The endogenous neomycin phosphotransferase II expressed by 293T cells was not
visible at this exposure. One of three equivalent experiments is shown.
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(D) Forty-eight hours after transfection with the constructs indicated, 293T cells were pulse-labelled (P) for 30 min with 35S-cysteine/methionine,
followed by a 2-h chase (C) with excess unlabelled cysteine/methionine. OVA derivatives were then immunoprecipitated with an OVA-specific
rabbit serum and resolved by SDS-PAGE. The specific bands corresponding to each fusion protein are indicated by arrowheads. The graph shows
densitometry readings for each band.
(E) 293T cells transfected with selected fusion proteins were labelled for a variable period (15–120 min) as indicated. OVA derivatives were then
immunoprecipitated and analysed as in (D). Arrowheads show the predicted position of the relevant fusion proteins for the 120-min label samples.
(F) Either SOVA-ORF73A or SOVA was transfected into 293T cells. Forty-eight hours later the cells were pulse-labelled (P) for 15 min with 35S-
cysteine/methionine, followed by a 15-min (C1), 45-min (C2), and 105-min (C3) chase with excess unlabelled cysteine/methionine. This was done
in the presence or absence of 100 lM lactacystin. The graph shows densitometry readings for each specific band.
DOI: 10.1371/journal.pbio.0030120.g002
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ORF73 coding region and used this to co-express either green
fluorescent protein (GFP) or three tandem MHC class I–
binding peptides (Figure 3A).
Southern blots confirmed the predicted genomic structure
of the ORF73-IRES-epitope (EPI) and ORF73-IRES-GFP
viruses (Figure 3B). Both mutants showed unimpaired growth
in vitro (Figure 3C). Infection of H2-Kb fibroblasts with the
EPI virus established that its SIINFEKL epitope could be
processed and presented (Figure 3D). MHV-68 expressing
OVA from an intergenic expression cassette under the
control of an ectopic viral M3 promoter (MHV-OVA), which
shows high-level lytic cycle OVA production (data not shown),
was tested in parallel. In murine embryonic fibroblast (MEF)-
1 cells, which support MHV-68 lytic replication, MHV-OVA
showed better SIINFEKL presentation than did the EPI virus.
In L929 cells, which support viral entry into the lytic cycle
relatively poorly [38], the EPI virus gave better SIINFEKL
presentation than did MHV-OVA. These data were consistent
with the EPI virus presenting SIINFEKL in latency.
The GFP mutant provided further evidence that the IRES
constructs were expressed in latency. Although MHV-68 is
predominantly latent in B cells in vivo, it appears to infect B
cells poorly in vitro. This may reflect that efficient infection
by MHV-68 virions requires cell-surface glycosaminoglycans
[39]. We therefore enhanced infection of the A20 B cell line
by transducing it with a retroviral vector expressing the
extracellular domain of syndecan-1, a major carrier of cell-
surface glycosaminoglycans [40], linked to the transmem-
brane and cytoplasmic domains of H2-Db. This form of
syndecan-1 resists proteolytic cleavage. GFP expressed from a
human cytomegalovirus IE-1 promoter [41] gave green
fluorescence in relatively few A20-syndecan-1 cells. Although
the ORF73-IRES-GFP virus gave much weaker fluorescence,
many more cells were positive (Figure 3E). These data were
consistent with B cell infection being predominantly latent,
and with gene expression from the IRES constructs in latency.
Epitope Presentation during Episome Maintenance Leads
to a Severe In Vivo Latency Deficit
We tested the capacity of the EPI virus to replicate in vivo
by intranasal infection of C57BL/6J mice (Figure 4). There was
no difference between wild-type (WT) and EPI viruses in lytic
replication in lung epithelial cells or in seeding latent virus to
the spleen (Figure 4A). However, by 14 d after infection, when
WT virus had reached its peak latent load, the titre of EPI
virus was drastically reduced (Figure 4B). In agreement with
the reduced number of infectious centres, the EPI virus
genome load was low (Figure 4C) and there was little virus-
driven B cell activation, T cell activation, or Vbeta4þCD8þ T
cell expansion (Figure 4D). The GFP control virus showed no
such deficit, so it was not the IRES element that compromised
ORF73 function. An independently derived EPI mutant
showed a similar in vivo latency deficit, and reverting the
EPI mutation restored latency establishment to normal levels
(Figure 4E). The latency deficit was therefore due specifically
to the expression of a poly-epitope construct downstream of
ORF73.
Figure 3. Modification of the MHV-68 Genome to Overcome cis-Acting
Immune Evasion by ORF73
(A) An IRES element was inserted just downstream of ORF73,
between its stop codon and that of M11. This allowed either three
tandem CD8þ T cell epitopes (EPI) or GFP to be translated from the
ORF73 mRNA.
(B) DNA from BAC-cloned viral genomes (BAC) or virus-infected cells
(VIR) was digested with NcoI, electrophoresed, transferred to nylon
membranes, and blotted with a probe corresponding to the BamHI-G
genomic fragment shown in (A). The predicted bands for WT virus
were 1,021 bp, 3,121 bp, and 4,630 bp. The IRES-GFP insert
introduced an NcoI site such that the WT 3,121-bp band was cut
into 2,975-bp and 1,466-bp fragments. The NcoI site was lost from the
IRES-EPI insert, such that the WT 3,121-bp band became a 3,861-bp
band.
(C) BHK-21 cells were infected (0.01 PFU/cell) with WT, GFP, or EPI
viruses as indicated. Plaque titres of cell cultures are shown with time
after infection.
(D) H2b MEF-1 cells or L929-Kb cells were left uninfected (UI) or
infected for 2 h with MHV-68 expressing either OVA under a strong
lytic promoter (OVA) or the SIINFEKL epitope of OVA as part of the
ORF73-IRES-EPI construct (EPI). B3Z cells were then added, and 18 h
later their beta-galactosidase response was assayed using chlorophe-
nol-red-beta-D-galactoside substrate. Mean 6 SD values of triplicate
cultures are shown. The data are from one or two equivalent
experiments.
(E) A20-syndecan-1 cells were infected (20 PFU/cell) with GFP WT
virus, WT virus with an HCMV IE1 promoter-driven GFP expression
cassette (HCMV IE1-GFP), or with the ORF73-IRES-GFP virus. The
numbers indicate the percentage of total cells in the gated region
(GFPþ). Expression from the HCMV IE1 promoter is probably limited
to lytic infection, whereas ORF73 is expressed in latency.
DOI: 10.1371/journal.pbio.0030120.g003
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Figure 4. Replication of the IRES-EPI Virus In Vivo
(A) Six days after intranasal infection with WT or EPI viruses as
indicated, infectious virus in lungs was titred by plaque assay (left
panel) and infectious plus latent virus in spleens was titred by
infectious centre assay (right panel). Each point shows an individual
mouse. Pre-formed, infectious virus was undetectable in equivalent,
freeze-thawed spleen samples, so the infectious centres represent
latent virus.
(B) By 14 d post-infection, infectious centre titres were much lower
with the EPI virus than with WT. The GFP control virus is shown for
comparison. This difference was preserved at day 19 post-infection,
indicating that the EPI virus was not merely delayed in host
colonisation.
(C) DNA was extracted from spleens and its viral genome content
quantitated by real-time PCR. Genome loads broadly reflected the
infectious centre titres, indicating that the viral load was reduced
rather than the efficiency of ex vivo reactivation.
Figure 5. Antigen-Specific Immune Responses to the IRES-EPI Virus
(A) CD8þ and CD4þ T cell responses were measured by interferon-
gamma ELISPOT assay 13 d post-infection. The response to virus-
exposed targets (VIR) is mediated by CD4þT cells; the response to the
p56, p79, and SIINFEKL (OVA) peptides is mediated by CD8þ T cells
[62]. The mean number of spots with untreated targets was subtracted
from the number of spots with each specific target. There was a
response to the OVA peptide in the IRES-epitope construct, but not
to the ASNENMETM peptide (NP). Mean6 SD values of five mice per
group are shown.
(B) Total and MHV-68 virion-specific serum IgG responses were
measured by ELISA at 18 d post-infection. ‘‘Naive’’ indicates age-
matched, uninfected controls. Mean 6 SD absorbance values of four
mouse sera per group are shown.
(C) Spleen cells were stimulated for 5 h in the presence of Brefeldin A
plus the peptide indicated and then stained for cell-surface CD8 and
intracellular interferon-gamma. The percentage of interferon-
gammaþ CD8þ cells without peptide was subtracted from the value
with peptide to give the specific response. Mean 6 SD values of five
mice per group are shown.
DOI: 10.1371/journal.pbio.0030120.g005
(D) As a further measure of host colonisation, we measured B cell
activation (CD69 expression on CD19þ B cells) at 14 d post-infection
and CD8þ T cell activation (loss of CD62L expression) at 19 d post-
infection. We also measured the day 19 expansion of the
Vbeta4þCD8þ T cell subset that is characteristic of MHV-68-
associated infectious mononucleosis. All these measures correlated
closely with the viral latent load in lymphoid tissue and were
markedly reduced with the EPI virus compared to WT or GFP. GFP
expression was undetectable in ex vivo B cells after infection with the
GFP virus (data not shown).
(E) C57BL/6J mice were infected intranasally with WT virus, the EPI
mutant, an independently derived EPI mutant (EPI-IND), or a
revertant of the EPI virus (EPI-REV). Splenic infectious centres were
then measured 13 and 17 d post-infection. The dashed line shows the
lower limit of assay sensitivity.
DOI: 10.1371/journal.pbio.0030120.g004
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Antigen-Specific Immune Responses to the EPI Virus
The EPI virus was notably controlled without a need for the
massive T cell activation that characterises MHV-68- or EBV-
associated infectious mononucleosis (Figure 4D). We meas-
ured virus-specific immune responses (Figure 5) to gain some
idea of what effector response might be responsible for the
latency amplification deficit. At 13 d post-infection, ELISPOT
assays (Figure 5A) showed a low CD4þ T cell response to the
EPI virus compared to WT. A similar reduction in CD4þT cell
response is seen with MHV-68 specifically made to be latency
deficient [42], presumably because lytic reactivation after
latency amplification normally provides a large CD4þ T cell
stimulus. Virus-specific serum antibody titres were marginally
higher in the EPI-virus-infected mice (Figure 5B). CD8þ T cell
responses to immunodominant MHV-68 lytic epitopes (p56
and p79) were comparable between WT and EPI viruses at day
13 post-infection (Figure 5A and 5C). Thus, the EPI virus was
most likely being cleared by CTLs directed against an ORF73-
associated epitope.
There was no ASNENMETM-specific response to the EPI
virus (Figure 5A and 5C). Also, there was no evidence of an
enhanced response to the p79 epitope, which was present
both in the IRES-epitope construct and in its native context
in ORF61 [43]. These epitopes were probably not processed
from the polytope construct, since transfecting it as an
expression plasmid into H2-Kb- or H2-Db-expressing L929
cells stimulated the SIINFEKL-specific hybridoma B3Z but
not T cell hybridomas specific for ASNENMETM or p79 (data
not shown). In contrast to the lack of response to ASNEN-
METM, there was a clear response to the SIINFEKL epitope
co-expressed with ORF73 (Figure 5A and 5C), which was also
presented in vitro (see Figure 3D). By 18 d post-infection
(Figure 5C), the CD8þ T cell response to WT infection had
made its characteristic shift in immunodominance from the
p56 epitope associated with epithelial infection to the p79
epitope associated with B cell infection [43]. This did not
occur with the EPI virus, presumably because the number of
latently infected B cells remained low. Thus, it seemed likely
that SIINFEKL-specific CTLs eliminated the EPI virus.
Attenuation of the EPI Virus Is H2-Type-Restricted
As all of the CTL epitopes in the IRES-epitope construct
were H2b-restricted, a major prediction was that the EPI virus
would not be attenuated in H2d mice. This was found to be
the case (Figure 6). In H2d BALB/c mice, the EPI virus
attained infectious centre titres in the spleen equivalent to
WT virus (Figure 6A). B cell activation (Figure 6B), spleno-
megaly (Figure 6C), and viral genome load (Figure 6D) were
also normal. We further assayed latency by in situ hybrid-
Figure 6. Normal EPI Virus Replication in Non-H2b Mice
(A) Infectious centre titres in individual spleens were determined 14
d after intranasal infection of C57BL/6J (H2b) or BALB/c (H2d) mice
with WT or EPI virus.
(B) CD69 expression on splenic B cells was measured by flow
cytometry 14 d post-infection. B cells from uninfected mice were less
than 5% CD69þ.
(C) The weights of individual spleens are shown 14 d post-infection,
with spleens of age-matched, uninfected mice (UI) for comparison.
(D) Viral genome loads in individual mice were determined by real-
time PCR at 14 d post-infection.
(E) Viral tRNA expression in infected germinal centres was visualised
by in situ hybridization with a digoxigenin-labelled riboprobe specific
for tRNAs 1–4. Representative follicles of at least five sections per
mouse and three mice per group are shown. tRNAþ follicles were
abundant with WT virus and with the EPI virus in BALB/c mice, but
were not seen with the EPI virus in C57BL/6J mice.
(F) BALB/c or C57BL/6J mice were infected intranasally with MHV-68
expressing OVA from an intergenic expression cassette (OVA) or
with WT virus. The extent of lymphoid colonisation was determined
by infectious centre assay of spleens 12 and 15 d post-infection. Mean
6 SEM titres of five mice per group are shown. In contrast to the EPI
virus, the OVA virus showed no defect in host colonisation.
DOI: 10.1371/journal.pbio.0030120.g006
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ization for the expression of viral tRNA homologues in
splenic germinal centres (Figure 6E). These are expressed at
high levels in MHV-68-infected lymphoid tissue and provide
an additional marker of latency establishment [44]. The EPI
virus showed no viral tRNAþ cells in C57BL/6J mice and
normal numbers in BALB/c mice. These data supported the
idea that the attenuation of the EPI virus was due to the
expression of a CTL target from the ORF73 mRNA.
In contrast to the EPI virus, MHV-OVA showed no
significant attenuation in either BALB/c or C57BL/6J mice
compared to WT virus (Figure 6F). MHV-OVA expresses the
SIINFEKL epitope at high levels during lytic infection (see
Figure 3D). Thus, SIINFEKL expression during episome
maintenance, when epitopes are not normally presented,
was catastrophic for the virus, whereas SIINFEKL expression
outside of this context, when MHV-68 does not rely on
limiting epitope presentation for its survival, had little effect.
Attenuation of the EPI Virus Is CD8þ T Cell–Dependent
The MHC class I restriction of the EPI virus’s latency deficit
and its association with anti-SIINFEKL immunity implied
that CD8þT cells were eliminating latently infected cells. This
was confirmed by rescuing the EPI virus with CD8þ T cell
depletion (Figure 7). Thus, in C57BL/6J mice treated with an
anti-CD8 monoclonal antibody, the EPI virus achieved WT
levels of B cell activation (Figure 7A), viral genome load
(Figure 7B), and infectious centres (Figure 7C). The ORF73
CTL evasion (see Figure 1) that was bypassed in the EPI virus
was therefore essential for in vivo episome maintenance.
Discussion
The MHV-68 ORF73 lacks the glycine–alanine repeat of
EBNA-1 but still conferred poor presentation on a linked
CTL epitope. Thus, despite different means, MHV-68 and
EBV have arrived at a similar end of inhibiting epitope
presentation during episome maintenance. Neither molec-
ular mechanism is fully understood, but both seem to rely
primarily on limiting protein synthesis. A large proportion of
CTL epitopes are derived from abortive translation events
[45]. Understanding the mechanism of cis-acting CTL evasion
therefore means understanding the major source of abortive
translation events, whether damaged RNA, ribosomal errors,
or protein misfolding. Since the key evasion regions of
Figure 7. Rescue of the EPI Virus by CD8þ T Cell Depletion
Mice were left undepleted (UD) or depleted of CD8þ T cells (CD8) by an initial intravenous injection of mAb YTS169 2 d before infection,
followed by intraperitoneal injections of the same antibody every 2–3 d up to the time of sampling. Infection was by intranasal inoculation of
either WT or EPI viruses.
(A) Depletion was 95%–99% complete as assessed by flow cytometry of spleen cells. CD69 expression on splenic B cells was measured 13 d post-
infection.
(B) Genome loads were measured 13 d post-infection by real-time PCR. Each point shows an individual mouse.
(C) The infectious centre titres of individual mice at 13 d post-infection are shown for one of two equivalent experiments. The titres of pre-
formed, infectious virus in freeze-thawed spleens were less than 5% of the infectious centre titres, so even after CD8þ T cell depletion, the
infectious centre assay essentially measured latent virus. By 13 d post-infection, the lungs of both immunocompetent and CD8þ T cell–depleted
mice were clear of infectious virus.
(D) In situ hybridization for viral tRNA expression in splenic germinal centres is shown 13 d after infection of CD8þ T cell–depleted or
undepleted mice, infected with either EPI or WT virus. Spleens of two representative mice are shown in each case.
DOI: 10.1371/journal.pbio.0030120.g007
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EBNA-1 and ORF73 are located centrally, they are translated
only after potential N-terminal epitopes, and so may exert
their inhibitory effects prior to translation, as RNA. Our aim
here was to ask what cis-acting evasion contributes to the
fitness of a gamma-herpesvirus. Inserting an IRES element
downstream of ORF73 allowed us to bypass cis-acting
immune evasion in MHV-68. CTLs then wiped out latency.
We conclude that avoiding epitope presentation during
episome maintenance is fundamental to gamma-herpesvirus
survival.
As yet, no endogenous CTL epitopes to our knowledge
have been described for the MHV-68 ORF73. This may reflect
its cis-acting immune evasion in the same way that EBV
infection was initially thought not to elicit EBNA-1-specific
CTLs [46,47]. However, EBNA-1 epitopes can be presented by
cross-priming [5]. It seems likely that MHV-68 will elicit
ORF73-specific CTLs by a similar route. Certainly there is no
lack of predicted cleavable, MHC class I–binding peptides in
ORF73; for example, H2-Db, FSSTHPYTL; H2-Kb,
QCVTYYLL; H2-Dd and H2-Kd, KYQGMRRHL; and H-Ld,
APPSPDVDV. Thus, evasion must occur at the level of
endogenous ORF73 presentation.
The effectiveness of immune evasion is inevitably context-
dependent. Defining its impact on host colonisation there-
fore requires natural thresholds of in vivo antigen presenta-
tion. The results are not always predictable. For example,
MHV-68 transcribes its K3 gene in the lytic cycle as well as in
latency, but a lack of K3 has no discernable impact on
primary lytic infection, only on latency amplification [31].
The recognition of EBNA-1 during latency III [7,8,9] does not
necessarily imply EBNA-1 recognition during latency I, when
autoregulation [48] and a cell cycle dependence [49] of the Qp
promoter reduce EBNA-1 transcription. Our results with
MHV-68 suggest that the EBNA-1 glycine–alanine repeat is a
key component of in vivo EBV persistence. Of course MHV-
68 is not EBV, and it is possible that the expression of a strong
MHC class I–binding peptide exaggerated somewhat the
potential of ORF73-specific CTLs to control infection.
However, a clear message is that cis-acting CTL evasion is
an important feature of the gamma-herpesvirus lifecycle.
Latency-associated trans-acting CTL evasion comes into
play during the MHV-68 growth program, when rapid cell
division probably raises ORF73 production above a level that
can be disguised by cis-acting evasion, and additional viral
gene products are expressed. This trans-acting evasion allows
latency amplification to progress despite evidence of a CTL
response to at least one viral growth program antigen [32].
However, trans-acting evasion alone was insufficient for even
an initial amplification of MHV-68 latency. SIINFEKL
production from the EPI virus did not simply compromise
K3 function, since a complete loss of K3 typically gives a 1-log
reduction in infectious centres with relatively little effect on
the viral genome load [31], whereas the EPI virus showed a 3-
to 4-log infectious centre deficit and a severely reduced
genome load. cis-acting immune evasion therefore operated
in a distinct setting relatively early in latency establishment.
Multiple patterns of both EBV [50,51] and MHV-68 [14] latent
gene expression occur in acutely infected lymphoid tissue.
Notably, EBV implements EBNA-1-only latency even during
acute infectious mononucleosis [35]. Thus, the extreme
dependence of MHV-68 on cis-acting evasion probably
reflects early B cell entry into ‘‘ORF73-only’’ latency.
The rather modest SIINFEKL-specific response to the EPI
virus contrasted with the massive CTL activation stimulated
by WT virus. For example, in one experiment WT virus
progressed from 4.73103 infectious centres per spleen at day
10 of infection to 6.4 3 104 at day 14 (means of five mice),
while the percentage of CD8þ T cells expressing CD69
increased from 10.7% to 20.8%. Over the same time, the
EPI virus infectious centres fell from 7.3 3 102 to 4.6 3 101,
with 6.9% and 5.9%, respectively, of CD8þ T cells expressing
CD69. Indeed the numerous lytic antigen-specific CTLs
stimulated by EBV [52] and MHV-68 [43] infections imply
an immune response failure, since latently infected B cells
proliferate and progress to lytic gene expression without
hindrance by latent antigen-specific CTLs. It is crucial in
persistent viral infections for the immune system to attack
appropriate targets. End-stage cells may stimulate large T cell
responses, but the control of infection depends more on
overcoming immune evasion. A major challenge in vaccinat-
ing against complex pathogens is to direct the immune
system against the key, self-renewing population that main-
tains the parasite load.
Materials and Methods
Mice. C57BL/6J and BALB/c mice (Harlan Olac, Bicester, United
Kingdom) were kept in Cambridge University animal facilities in
accordance with United Kingdom Home Office guidelines (project
licence 80/1579). Mice were infected intranasally with 23 104 plaque-
forming units (PFU) of MHV-68 under brief halothane anaesthesia. T
cell subset depletion was by intravenous and then intraperitoneal
injection of purified mAb YTS169 [53].
Cell lines. BHK-21 cells, MEF-1 cells, NIH-3T3-CRE cells [31], A20
cells, L929 cells transfected with H2-Kb [54], and the B3Z T cell
hybridoma [55 were all grown in DMEM, supplemented with 2 mM
glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin, and 10%
fetal calf serum (complete DMEM). A20-syndecan-1 cells were made
by retroviral transduction of A20 cells with a vector expressing the
extracellular domain of murine syndecan-1 linked to the trans-
membrane and cytoplasmic domains of H2-Db, and will be described
in detail elsewhere. MEFs were harvested at 13 d of gestation and
were grown in complete DMEM with 50 lM 2-mercaptoethanol.
Plasmids.We amplified ORF73 by PCR (Hi-Fidelity PCR kit, Roche
Diagnostics, Lewes, United Kingdom), including EcoRI and SalI
restriction sites at its respective 59 and 39 ends, and cloned the
product into the EcoRI and SalI sites of pSP73 (Promega, Chilworth,
United Kingdom) to make pSP73-ORF73. To introduce the SIINFEKL
epitope of OVA [56] near the 39 end of ORF73, we digested pSP73-
ORF73 with HinDIII and dephosphorylated it (P. borealis alkaline
phosphatase, Roche Diagnostics). Two complementary oligonucleo-
tides (59-AGCTAGTATAATCAACTTTGAAAAACTGCT and 59-AGC-
TAGCAGTTTTTCAAAGTTGATTATACT) (Sigma-Genosys,
Cambridge, United Kingdom) were then heated, annealed, phos-
phorylated, and ligated into the HinDIII site (T4 DNA ligase, New
England Biolabs, Hitchin, United Kingdom). Thus, amino acid
residues 277–283 of ORF73 (QASGTQH) were changed to QASIIN-
FEKLLASGTQH (ORF73-SC). Oligonucleotide insertion was con-
firmed by DNA sequencing. To insert the SIINFEKL coding sequence
in the 59 end of ORF73, we amplified ORF73 by PCR, pairing the 59
primer ATCGAATTCAGATAATGCAAGCTTCCCCACCGACT, con-
taining a 59 EcoRI restriction site (underlined) upstream and a
HinDIII site (double-underlined) downstream of the ORF73 start
codon (bold), with a 39 primer downstream of the ORF73 BstEII site,
and containing an XhoI site. This PCR product was cloned into the
EcoRI and XhoI sites of pSP73. The complementary oligonucleotides
59-AGCTAGTATAATCAACTTTGAAAAACTGAC and 59-AGCTGT-
CAGTTTTTCAAAGTTGATTATACT were then inserted into the
HinDIII site, changing amino acid residues 1–6 of ORF73 from
MPTSPP to MQASIINFEKLTASPP (ORF73-SN). The modified 59 end
of ORF73 was then subcloned as an EcoRI/BstEII fragment into
pSP73-ORF73, thereby reconstituting the gene with its 39HinDIII site
intact. Each form of ORF73 was then cloned into the pcDNA3
mammalian expression vector (Invitrogen, Carlsbad, California,
United States). We made 39 deletions of pcDNA3-ORF73-SN by
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digesting it with HinDIII or KpnI, each of which cuts within ORF73
and within the pcDNA3 polylinker 59 of its EcoRI site. The N-
terminal ORF73 fragment was then gel-purified and ligated into a
new pcDNA3 vector. We generated a 39 PstI deletion by digestion
with PstI, gel purification, and ligation of the vector back to itself,
since PstI cuts downstream of the pcDNA3 XhoI site.
We subcloned the N-terminal 325 amino acid residues of OVA as
an EcoRI/XhoI fragment from pMSCV-OVA-IRES-GFP [57] into
pSP73. Hybrids of 59 ORF73 and 39 OVA (which contains the
SIINFEKL epitope), or 59 OVA and 39 ORF73 (with its SIINFEKL
insert), were made by cutting each at a unique internal PstI site and
swapping an in-frame 39 PstI/XhoI fragment between them. Each
form of ORF73/OVA was then subcloned as an EcoRI/XhoI fragment
into the EcoRI and XhoI sites of pcDNA3. To fuse the ORF73 coding
sequence to the C-terminus of OVA, we PCR-cloned the N-terminal
325 amino acid residues of OVA without a stop codon into the EcoRI
and XhoI sites of pcDNA3 and ligated in PCR-cloned ORF73 as an
XhoI/ApaI fragment, downstream of and in frame with the OVA
coding sequence. 39 HinDIII and KpnI truncations of this construct
were generated as above. We also generated 59 ORF73 truncations as
XhoI/ApaI-digested PCR products, starting at amino acid residue 126
(OVA-73E), 146 (OVA-73D), 166 (OVA-73C), 186 (OVA-73B), or 206
(OVA-73A), and fused these to OVA 1–325 in pcDNA3. We also
cloned OVA lacking its signal sequence, with translation starting at its
methionine residue 41 (SOVA), and made the same fusions with N-
terminal ORF73 truncations A–E.
Recombinant viruses. The MHV-68 M11 and ORF73 coding
sequences (genomic co-ordinates 103418–103933 and 104868–
103924, respectively) overlap by 10 bp at their 39 ends [11]. We
therefore duplicated this overlap to generate an insertion site
between them. Thus, we PCR-cloned genomic co-ordinates 131171–
103933, including XhoI and SalI restriction sites at the respective 59
and 39 ends, and cloned the fragment into the XhoI and SalI sites of
pSP73-ORF73 (see Plasmids, above) to make pSP73-ORF73-M11, with
the M11 and ORF73 coding sequences each complete and separated
by a SalI site. The M11/ORF73 genomic overlap TTTATGTCTGAG
(the stop codons of ORF73 on the noncoding strand and M11 on the
coding strand are underlined) was thus changed to TTTATGTC-
TGAGTCGACTTATGTCTGAG. We then generated a poly-epitope
construct downstream of an encephalomyocarditis IRES for insertion
into the SalI site. We first inserted the adenovirus E19K leader
sequence as two complementary oligonucleotides (59-AATTGAC-
CACCATGAGGTACATGATTTTAGGCTTGCTCGCCCTTGCG-
GAGTCTGCAGCGCGAATTCAGATCTCTCGAGTGAT and 59-
TCGAATCACTCGAGAGATCTGAATTCGCGCTGCAGACTGCCG-
CAAGGGCGAGCAAGCCTAAAATCATGTACCTCATGGTGGTC)
into the EcoRI and XhoI sites of pMSCV-IRES-NEO [57]. Two
complementary oligonucleotides encoding the peptide sequence
MTSINFVKIASNENMETMSIINFEKL (59-AATTCCTACCACCAT-
GACCAGTATCAACTTTGTGAAGATAGCTTCCAATGAAAACATG-
GAGACTATGAGTATAATCAACTTTGAAAAACTGTGAC and 59-
TCGAGTCACAGTTTTTCAAAGTTGATTATACTCATAGTCTC-
CATGTTTTCATTGGAAGCTATCTTCACAAAGTTGATACTGGT-
CATGGTGGTAG) were then inserted into the EcoRI and XhoI sites
of the pMSCV-NEO-leader construct. TSINFVKI is an H2-Kb-
restricted epitope from the MHV-68 ORF61 [43]; ASNENMETM is
an H2-Db-restricted epitope from the influenza A/PR/8/34 nucleo-
protein [58]. We amplified the leader-epitope construct by PCR, using
t h e p r ime r s 5 9- CCCCCATGGCCAGGTACATGATTT -
TAGGCTTGCTC and 59-CCCGTCGACTCACAGTTTTTCAAAGTT-
GATTATACT, thereby adding a 59 NcoI site and replacing the 39
XhoI site with a 39 SalI site, and cloned it into the NcoI and SalI sites
of pMSCV-IRES-GFP [59]. Thus, the GFP coding sequence down-
stream of the IRES was replaced by the leader-epitope construct. We
used the 39 SalI site and an XhoI site just 59 of the IRES to excise an
IRES-leader-epitope XhoI/SalI fragment and cloned it into the SalI
site of pSP73-ORF73-M11. We also subcloned an XhoI/SalI IRES-GFP
fragment from pMSCV-IRES-GFP into the SalI site of pSP73-ORF73-
M11 to make a control virus. Each ORF73-IRES construct was then
subcloned into a larger genomic fragment for recombination into the
MHV-68 genome. To do this, we used a BamHI-G genomic fragment
[10] (genomic co-ordinates 101653–106902), cloned into pACYC184
(New England Biolabs) lacking a BspHI site [60]. The ORF73-IRES
constructs and pACYC184-BamHI-G were digested with BstEII
(genomic co-ordinate 104379) and BspHI (genomic co-ordinate
103750). Because BspHI is blocked by methylation, we used plasmids
derived from Dam E. coli. Finally, the mutant BamHI-G fragments
were subcloned into the BAC mutagenesis shuttle vector pST76K-SR.
Rec A–mediated recombination into the MHV-68 BAC was then
carried out as previously described [41]. Sequence analysis revealed
that the E19K leader sequence had been mutated during cloning,
destroying the NcoI site and changing the start of the coding
sequence downstream of the IRES from MARYMILG to MILG. Since
this change was unlikely to prevent epitope presentation, no attempt
was made to correct it. The ORF73-IRES-epitope BAC was
subsequently reverted using an unmutated BamHI-G clone in
pST76K-SR. MHV-OVA was generated by cloning OVA cDNA into
EcoRI and XhoI sites of an ORF57/ORF58 intergenic expression
cassette, driven by an ecotopic MHV-68 M3 promoter [61]. This virus
will be described in more detail elsewhere. All BACs were
reconstituted into infectious virus by transfecting 5 lg of BAC
DNA into BHK-21 cells with Fugene-6 (Roche Diagnostics). The BAC
cassette was removed by serial viral passage through NIH-3T3-CRE
cells. Virus stocks were grown and titred on BHK-21 cells.
Virus assays. Infectious virus in freeze-thawed lung and spleen
homogenates was plaque assayed on MEFs. Latent plus pre-formed
virus in spleens was assayed on MEFs by explant culture of single-cell
suspensions [39]. Cells expressing viral tRNAs 1–4 were detected by in
situ hybridization of formalin-fixed, paraffin-embedded spleen cell
sections, using a digoxigenin-labelled riboprobe transcribed from
pEH1.4 [44]. Hybridized probe was detected with alkaline phospha-
tase-conjugated anti-digoxigenin Fab fragments (Boehringer Ingel-
heim, Bracknell, United Kingdom) according to the manufacturer’s
instructions. The viral genome load in individual spleens was
measured by real-time PCR. DNA was extracted (Wizard genomic
DNA purification kit, Promega) and a portion of the MK3 ORF
(genomic co-ordinates 24832–25071) amplified by PCR from 10 ng of
each sample (Rotor Gene 3000, Corbett Research, Cambridge, United
Kingdom). PCR products were quantitated with Sybr green (Invi-
trogen) and compared with a standard curve of cloned MK3 template,
serially diluted in uninfected cellular DNA and amplified in parallel.
The MK3 copy number was calculated from the cycle number at
which the Sybr green signal crossed a set threshold on the standard
curve. Amplified products were distinguished from paired primers by
melting curve analysis, and the correct size of the amplified products
was confirmed by electrophoresis and staining with ethidium
bromide.
Southern blotting. Viral DNA was isolated from infected BHK-21
cells by alkaline lysis [39], digested with NcoI, electrophoresed on a
0.8% agarose gel, and transferred to positively charged nylon
membranes (Roche Diagnostics). A 32P-dCTP-labelled probe (APBio-
tech, Amersham, United Kingdom) was generated from the BamHI-G
genomic fragment by random primer extension (Nonaprimer kit,
Qbiogene, Bingham, United Kingdom) according to the manufac-
turer’s instructions. Membranes were hybridized with probe (65 8C,
18 h), washed to a stringency of 0.23SSC with 0.1% SDS, and exposed
to X-ray film.
Metabolic labelling and immunoprecipitation. Cells were metabol-
ically pulse-labelled with 35S-cysteine/methionine (APBiotech) and
chased with 1 mM unlabelled cysteine and methionine [29]. Labelled
cells were lysed on ice for 30 min in 50 mM Tris-Cl (pH 7.4), 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM PMSF, plus Complete
protease inhibitors (Roche Diagnostics). Cell debris and nuclei were
removed by centrifugation (13,000 3 g, 15 min). Lysates were
precleared with rabbit anti-actin whole serum and formalin-fixed S.
aureus (Sigma Chemical, Poole, United Kingdom), and then again
with protein A-sepharose. OVA was precipitated with rabbit anti-
OVA serum (Abcam, Cambridge, United Kingdom) followed by
protein A-sepharose. Beads were washed five times in 1% Triton X-
100 buffer. Samples were dissociated (95 8C, 2 min) in Laemmli’s
buffer prior to SDS-PAGE. Gels were fixed, dried, and exposed to X-
ray film.
Immunoblotting. Cells were lysed as for immune precipitations
(above). Post-nuclear lysates were denatured (95 8C, 2 min) in
Laemmli’s buffer, separated by SDS-PAGE, and transferred to
polyvinylidene difluoride membranes. Membranes were blocked in
PBS/0.1% Tween-20/10% non-milk fat and probed with rabbit anti-
OVA serum or rabbit anti-neomycin phosphotransferase II serum
(Upstate, Milton Keynes, United Kingdom), followed by horseradish-
peroxidase-coupled donkey anti-rabbit IgG pAb (APBiotech) and
ECL substrate development.
Antigen presentation assays. L929-Kb cells (1–2 3 105/well in 24-
well plates) were transfected with 1 lg of plasmid using Fugene-6.
Forty-eight hours later, B3Z cells (5 3 105) were added to each well.
B3Z is an H2-Kb-restricted, SIINFEKL-specific T cell hybridoma that
produces beta-galactosidase in response to T cell receptor ligation
[55]. For virus infections, L929-Kb cells or MEF-1 cells (5 3 105/well)
were infected for 2 h and washed once before adding B3Z T cell
hybridoma cells (5 3 105/well). After a further 18 h, the cells were
washed once in PBS and lysed in PBS/5 mM MgCl2/1% NP-40/0.15 lM
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chlorophenol-red-beta-D-galactoside (Merck Biosciences, Notting-
ham, United Kingdom) to assay beta-galactosidase activity. After 2–
4 h at 37 8C, the absorbance at 595 nm was read on a Bio-Rad
(Hercules, California, United States) Benchmark microplate reader.
ELISA and ELISPOT assays. For IFN-c ELISPOT assays [62],
duplicate dilutions of effector cells were incubated with 33 105 naive
irradiated syngeneic spleen cells in nitrocellulose-bottomed 96-well
plates (Millipore Corporation, Bedford, Massachusetts, United States)
coated with rat anti-mouse IFN-c mAb (BD-Pharmingen, San Diego,
California, United States). The naive spleen cells were either (1)
untreated, (2) pulsed with 1 lM AGPHNDMEI (p56), 1 lM TSINFVKI
(p79), 1 lM ASNENMETM, or 1 lM SIINFEKL peptide, or (3) infected
with WT MHV-68 (2 PFU/cell). After 48 h culture at 37 8C in complete
RPMI/50 lM 2-mercaptoethanol/10 U/ml human recombinant IL-2,
captured IFN-c was detected with a further, biotinylated rat anti-
mouse IFN-c mAb (BD-Pharmingen), followed by streptavidin-
alkaline phosphatase (Dako Cytomation, Ely, United Kingdom) and
5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium sub-
strate.
Virus-specific and total serum IgG levels were measured by ELISA.
Maxisorp ELISA plates (Nalge Nunc, Rochester, New York, United
States) were coated overnight with either affinity-purified goat anti-
mouse IgG sera (Sigma Chemical) or 0.05% Triton X-100–disrupted
MHV-68 [63]. After incubation with 2-fold serum dilutions, bound
murine IgG was detected with alkaline phosphatase-conjugated goat
anti-mouse IgG–Fcc serum and nitrophenylphosphate substrate
(Sigma Chemical). Absorbance was read at 405 nm.
Flow cytometry. A20-syndecan-1 cells infected with GFPþ viruses
were trysinized, washed in PBS, and analysed directly for green
channel fluorescence. Spleens were disrupted into single-cell suspen-
sions, washed in PBS/0.1% BSA/0.01% azide, and incubated for 15
min on ice with 5% mouse serum/5% rat serum and anti-CD16/32
mAb. Specific staining (1 h, 4 8C) was with fluorescein-isothiocyanate-
coupled anti-CD69 and phycoerythrin-coupled anti-CD19 (BD-
Pharmingen), or tricolour-coupled anti-CD8 (Caltag Laboratories,
Burlingame, California, United States), Fluorescein-isothiocyanate-
coupled anti–T cell receptor Vbeta4, and phycoerythrin-coupled
anti-CD62L (BD-Pharmingen). For intracellular cytokine staining,
spleen cells (5 3 105–1 3 106 in 200 ll of complete RPMI/50 lM 2-
mercaptoethanol/10 U/ml human recombinant IL-2/10 lg/ml Brefel-
din A) were stimulated (5 h, 37 8C) with 1 lM ASNENMETM, 1 lM
AGPHNDMEI, 1 lM TSINFVKI, or 1 lM SIINFEKL peptides, or left
without peptide. All cells were then washed in PBS/10 lg/ml Brefeldin
A, blocked with anti-CD16/32, stained with tricolour-conjugated anti-
CD8 plus fluorescein-isothiocyanate-conjugated anti-I-Ab (1 h, 4 8C),
washed twice, fixed in 2% paraformaldehyde (30 min, 4 8C), washed
once, permeabilized with 0.5% saponin, washed once, stained with
phycoerythrin-coupled anti-interferon-gamma (BD-Pharmingen), and
washed twice. All cells were analysed on a FACSCalibur usingCellquest
software (Becton-Dickinson, Oxford, United Kingdom). I-Ab staining
was used to exclude B cells and myeloid cells. Data were graphed with
FCSPress v1.3 (www.fcspress.com).
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